4.7 Article

Design and Application of Rolling Circle Amplification for a Tumor-Specific Drug Carrier

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 58, Issue 19, Pages 7863-7873

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b01126

Keywords

-

Funding

  1. KIST Institutional Program [2E25270]
  2. National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [1520100]
  3. Ministry of Science, ICT & Future Planning, Republic of Korea [2E25270] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

It is challenging to design rolling circle amplification (RCA) for tumor-selective delivery of drugs. Here, we devise a doxorubicin nanocarrier composed of RCA products, cholesterol-DNA, and folate-DNA conjugates. RCA products, designed to contain tandem repeats of short hairpin DNA, employ the repeated sequences complementary to both DNA conjugates, and thus RCA products/cholesterol-DNA/folate-DNA complexes, generated via sequential base pairing processes, acquire the amphiphilic properties that facilitate self-assembly into the highly condensed nanoparticles (RCA nanoparticles). Doxorubicin-loaded RCA nanopartides, especially with high cargo capacity, release drugs to the environment with the aid of acidity and show selective cytotoxicity to cancer cells. Particularly, the condensed structures enable RCA nanoparticles to be resistant to nucleases in the blood. These results show that RCA nanopartides have great potential as a doxorubicin carrier for targeted cancer therapy, and furthermore, our strategy provides an alternative tool to exploit RCA techniques on drug delivery systems.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available